glp-1 and diabetes Targeting GLP-1, GIP & GCG in Obesity Type 2 Research GLP-1 Receptor Agonists and Research
Description
Too much GLP-1 stimulation can lead to a prolonged delay in stomach emptying, which causes nausea or feelings of stomach discomfort, such as a sense of fullness, heartburn, or pain
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Acta Cardiol
These patches use the name GLP-1 to take advantage of the popularity of GLP-1 medications like Wegovy or Mounjaro
Husain M et al
Ros $149 membership bills the entire time
